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Abstract
Patients with intermediate-risk advanced renal cell carcinoma are a heterogeneous population, having either 1
or 2 risk factors. It is unclear whether all patients in this risk category should be treated similarly. A secondary
analysis of the PRINCIPAL study of pazopanib found that patients can be stratified by number of risk factors
and Eastern Cooperative Oncology Group performance status to more accurately predict outcomes.
Introduction: The objective of this study was to determine the effectiveness and safety of pazopanib in patients with
intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). Patients and
Methods: Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediate-risk International
Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and Memorial Sloan Kettering Cancer Center (MSKCC)
criteria. Assessments included progression-free survival, overall survival, objective response rate, and safety. We also
evaluated effectiveness based on number of risk factors, age, and performance status (PS), as well as safety in older
and younger patients. Results: Three hundred sixty three and 343 intermediate-risk MSKCC and IMDC patients were
included, respectively. The median progression-free survival was 13.8 months (95% confidence interval [CI], 10.7-18.1
months) and 7.4 months (95% CI, 6.2-10.3 months) for patients with 1 and 2 MSKCC risk factors, respectively, and 13.1
months (95%CI, 10.7-18.1 months) and 8.1months (95%CI, 6.4-10.7months) for patients with 1 and 2 IMDC risk factors,
respectively. Themedianoverall survivalwasnot reachedandwas15.2months (95%CI,12.3-26.5months) forpatientswith
1 and 2MSKCC risk factors, respectively, and 33.9months (95%CI, 33.9months to not estimable) and 19.4months (95%
CI, 14.3 months to not estimable) with 1 and 2 IMDC risk factors, respectively. A lower overall response rate was observed
with Eastern Cooperative Oncology Group PS  2 (vs. PS < 2). All-grade treatment-related adverse events occurred in
approximately 63% of patients, and the safety profile among older and younger patients was similar. Conclusions: Out-
comes with pazopanib in intermediate-risk patients suggest that patients can be further stratified by number of risk
factors (1 vs. 2) and Eastern Cooperative Oncology Group PS (< 2 vs.  2) to more accurately predict outcomes.
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Introduction outcomes. Indeed, previous retrospective analyses in intermediate-
Clinical outcomes for patients with advanced renal cell carcinoma
(RCC) have improved markedly since the introduction of agents
targeting vascular endothelial growth factor and its receptor,
mammalian target of rapamycin inhibitors, and immuno-oncologic
agents.1 Cytokine treatment was the standard of care prior to the
introduction of molecular targeted agents, and during that era, a
prognostic model was developed to predict survival in patients
treated with interferon-a in clinical trials at the Memorial Sloan
Kettering Cancer Center (MSKCC).2 The MSKCC model utilizes 5
clinical and laboratory pretreatment factors that independently
predict overall survival (OS) to categorize patients into favorable-risk
(0 risk factors), intermediate-risk (1-2 risk factors), or poor-risk ( 3
risk factors) prognostic groups.2 Although developed during the
cytokine era, the MSKCC prognostic model has since been vali-
dated for use with targeted agents.3 The International Metastatic
Renal Cell Carcinoma Database Consortium (IMDC) model is
another prognostic model developed from patients treated with first-
line vascular endothelial growth factor-targeted therapy (N ¼ 645)
and comprises 6 pretreatment clinical and laboratory factors.4
Similar to the MSKCC model, the IMDC model groups patients
into favorable-risk (0 risk factors), intermediate-risk (1-2 risk fac-
tors), or poor-risk ( 3 risk factors) groups, with significant dif-
ferences in survival across risk groups.4 The MSKCC and IMDC
risk classifications are widely used to estimate prognosis and are
becoming increasingly important for selecting treatments for pa-
tients with advanced RCC, as evidenced by several new agents now
available for patients with intermediate- or poor-risk RCC.5,6
Even as the tyrosine kinase inhibitors pazopanib and sunitinib are
standard first-line treatment options for patients with advanced
RCC,7,8 the phase III CheckMate-214 study recently demonstrated
superiority of nivolumab plus ipilimumab over sunitinib in patients
with IMDC intermediate or poor risk.5 Conversely, patients with
favorable risk in CheckMate-214 had significantly better outcomes
(progression-free survival [PFS] and objective response rate [ORR])
with sunitinib compared with nivolumab plus ipilimumab in an
exploratory analysis.5 Approximately one-half of patients with
advanced RCC have MSKCC or IMDC intermediate risk,4,9-11 and
discordant results between the favorable- and intermediate-risk
populations in CheckMate-2145 suggest that intermediate-risk pa-
tients may be further stratified to more accurately predict treatmentTable 1 Intermediate-risk Patient Disposition
MSKCC Interme
n [ 363
Patients who completed study 281 (77
Completed 30 months follow-up 133 (36
Deaths 148 (40
Patients who discontinued study 82 (22
Withdrawal of patient consent 31 (8.5
Physician request 8 (2.2
Lost to follow-up 29 (8.0
Other 14 (3.9
Abbreviations: IMDC ¼ International Metastatic Renal Cell Carcinoma Database Consortium; MSKCCrisk patients have demonstrated survival differences between pa-
tients with 1 versus 2 risk factors,10-12 supporting the heterogeneity
of this patient subgroup and justifying further analyses in pro-
spective datasets.
The large, prospective, observational PRINCIPAL study
(NCT01649778) confirmed the efficacy and safety of pazopanib in
a real-world clinical setting in 657 patients with advanced RCC.13
The objective of this secondary analysis of PRINCIPAL was to
evaluate the real-world effectiveness and safety of pazopanib within
MSKCC and IMDC intermediate-risk group patients with
advanced RCC.
Patients and Methods
Study Design and Patients
PRINCIPAL was a global, prospective, observational study of
patients with advanced/metastatic RCC treated with frontline
pazopanib. The study was designed to enrollw500 to 700 patients
over approximately 30 months. This sample size was chosen based
on the expected precision for the outcomes of interest (< 5% for
PFS, OS, and ORR) and the feasibility of enrolling the desired
patient population over the enrollment period. Consecutive patients
meeting eligibility criteria were enrolled at participating sites and
followed for 30 months or until premature discontinuation owing
to death, withdrawal of consent, loss to follow-up, or termination
from study. Patients who permanently discontinued study treat-
ment were followed for up to 30 months post-enrollment. Patients
were considered to have completed the study if 30 months of
follow-up were conducted, or if the patient died during the study
treatment or follow-up period.
Patients aged  18 years who have advanced/metastatic RCC of
clear-cell or predominantly clear-cell histology and who made a
clinical decision to initiate pazopanib within 30 days of enrollment
were eligible for participation in the PRINCIPAL study. These
secondary analyses included only patients who met MSKCC or
IMDC intermediate-risk criteria. Patients were classified as MSKCC
intermediate risk if they had 1 or 2 of the following risk factors2:
time from initial diagnosis to initiation of therapy < 1 year; Kar-
nofsky performance status (KPS) < 80%; serum hemoglobin
level < lower limit of normal (LLN); serum corrected calcium level
> 10 mg/dL; and lactate dehydrogenase level > 1.5 upper limit ofdiate Risk
(%)
IMDC Intermediate Risk
n [ 343 (%)
.4) 258 (75.2)
.6) 130 (37.9)
.8) 128 (37.3)
.6) 85 (24.8)
) 32 (9.3)
) 11 (3.2)
) 27 (7.9)
) 15 (4.4)
¼ Memorial Sloan Kettering Cancer Center.
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Table 2 Intermediate-risk Patient Baseline Demographics and Disease Characteristics
MSKCC Intermediate Risk
n [ 363 (%)
IMDC Intermediate Risk
n [ 343 (%)
Median age, y (range) 67.0 (22.0-89.0) 67.0 (22.0-90.0)
Male 256 (70.5) 243 (70.8)
Racea
White/Caucasian/European 347 (95.6) 323 (94.2)
Other 19 (5.2) 19 (5.5)
Unknown/declined to provide 0 2 (0.6)
Number of risk factorsb
1 147 (40.5) 171 (49.9)
2 141 (38.8) 133 (38.8)
Missing 75 (20.7) 39 (11.4)
ECOG performance status
< 2 333 (91.7) 316 (92.1)
 2 8 (2.2) 8 (2.3)
Not recorded 22 (6.1) 19 (5.5)
Median disease duration of RCC from initial diagnosis, y (range) 1.8 (0.0-27.9) 1.8 (0.0-27.9)
Median disease duration of locally advanced/metastatic RCC, y (range) 0.1 (0.0-23.1) 0.1 (0.0-23.1)
Metastases present 349 (96.1) 329 (95.9)
Median number of metastatic sites (range) 2.0 (0.0-15.0) 2.0 (0.0-15.0)
Location of metastatic sites
Lung 241 (66.4) 225 (65.6)
Lymph nodes 117 (32.2) 112 (32.7)
Bone 93 (25.6) 88 (25.7)
Liver 53 (14.6) 45 (13.1)
Adrenal glands 43 (11.8) 39 (11.4)
Brain 16 (4.4) 14 (4.1)
Other 91 (25.1) 88 (25.7)
Prior nephrectomy 287 (79.1) 273 (79.6)
First-line systemic therapy 18 (5.0) 14 (4.1)
Interleukin-2 3 (0.8) 1 (0.3)
Interferon-a 8 (2.2) 6 (1.7)
Other 7 (1.9) 7 (2.0)
Adjuvant/neoadjuvant systemic therapy
Adjuvant 2 (0.6) 3 (0.9)
Neoadjuvant 2 (0.6) 2 (0.6)
No 328 (90.4) 313 (91.3)
Not applicable 31 (8.5) 25 (7.3)
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; IMDC ¼ International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC ¼ Memorial Sloan Kettering Cancer Center;
RCC ¼ renal cell carcinoma.
aPatients may have indicated more than one race category.
bPatients with one missing risk factor were excluded.
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if they had 1 or 2 of the following risk factors4: time from initial
diagnosis to initiation of therapy < 1 year; KPS < 80%; serum
hemoglobin level < LLN; serum corrected calcium level > ULN;
absolute neutrophil count > ULN; and platelet count > ULN.
Missing KPS risk factor was imputed based on baseline Eastern
Cooperative Oncology Group (ECOG) performance status (PS)
score: if baseline ECOG PS < 2, then KPS risk factor ¼ no; if
baseline ECOG PS  2, then KPS risk factor ¼ yes.- Clinical Genitourinary Cancer June 2019All patients provided informed consent, and the study was con-
ducted in accordance with International Conference on Harmo-
nisation Good Clinical Practice, patient privacy requirements, and
ethical principles outlined in the Declaration of Helsinki 2008.
Assessments
There were no visits or procedures mandated by the protocol. At
the baseline visit, patient demographics, disease characteristics, and
medical history were collected. Follow-up information was obtained
Table 3 Subgroup Analysis of PFS and OS in Patients With Intermediate Risk at Baselinea
MSKCC Intermediate Risk IMDC Intermediate Risk
Disease Progression
or Death, N Median (95% CI), mos
Disease Progression
or Death, N Median (95% CI), mos
Progression-free survival
Number of risk factorsb
1 85/147 13.8 (10.7-18.1) 88/171 13.1 (10.7-18.1)
2 85/141 7.4 (6.2-10.3) 88/133 8.1 (6.4-10.7)
Age, y
< 65 79/142 12.3 (9.0-16.4) 73/136 13.1 (10.3-18.4)
 65 131/219 10.7 (9.0-13.8) 123/205 10.7 (9.0-13.1)
ECOG performance status
< 2 189/333 11.2 (9.5-14.1) 177/316 11.8 (9.9-15.4)
 2 8/8 5.6 (1.3-12.8) 8/8 2.3 (1.2-10.7)
Overall survival
Number of risk factorsb
1 46/147 NR (NE-NE) 51/171 33.9 (33.9-NE)
2 77/141 15.2 (12.3-26.5) 66/133 19.4 (14.3-NE)
Age, y
< 65 52/142 33.9 (27.0-33.9) 43/136 33.9 (NE-NE)
 65 95/219 30.5 (19.9-NE) 84/205 32.9 (26.0-NE)
ECOG performance status
< 2 132/333 33.9 (27.9-NE) 113/316 33.9 (30.5-NE)
 2 6/8 9.5 (1.3-NE) 7/8 5.0 (1.2-12.8)
Abbreviations: CI ¼ confidence interval; ECOG ¼ Eastern Cooperative Oncology Group; IMDC ¼ International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC ¼ Memorial Sloan
Kettering Cancer Center; NE ¼ not evaluable; NR ¼ not reached.
aAnalysis conducted in all treated (AT) population.
bPatients with 1 missing risk factor excluded.
Giuseppe Procopio et alapproximately every 3 months ( 4 weeks). Participating physicians
assessed tumor responses according to local processes and their own
clinical judgement. Primary effectiveness measures were PFS, OS,
and ORR (defined as complete response or partial response).Table 4 Subgroup Analysis of ORR in Patients With Intermediate R
MSKCC Intermediate Risk
ORR, n/N (%)
Median DOR, mos
(95% CI)
Median TT
(95% C
Number of risk
factorsb
1 42/124 (33.9) 15 (10.8-22.5) 3 (2.9-3
2 44/129 (34.1) 7 (4.6-21.3) 3 (2.7-3
Age, y
< 65 40/123 (32.5) 14 (5.8-19.3) 3 (2.7-3
 65 62/190 (32.6) 14 (8.8-22.3) 3 (2.8-3
ECOG performance
status
< 2 97/288 (33.7) 14 (7.2-19.1) 3 (2.9-3
 2 0/7 (0.0) NA NA
Abbreviations: DOR ¼ duration of response; ECOG ¼ Eastern Cooperative Oncology Group; MSKCC ¼
TTR ¼ time to response.
aAnalysis conducted in measurable disease (MD) population.
bPatients with 1 missing risk factor excluded.Patients who received  1 dose of pazopanib were evaluable for
PFS, OS, and safety analyses (all treated [AT] population). The
measurable disease (MD) population comprised patients with
measurable disease at baseline and was used for the ORR analysis.isk at Baselinea
IMDC Intermediate Risk
R, mos
I) ORR, n/N (%)
Median DOR, mos
(95% CI)
Median TTR, mos
(95% CI)
.5) 44/143 (30.8) 14 (7.5-22.5) 3 (2.9-3.2)
.2) 39/119 (32.8) 7 (4.4-20.1) 3 (2.7-3.2)
.4) 43/117 (36.8) 15 (5.8-19.3) 3 (2.9-3.5)
.1) 53/178 (29.8) 11 (7.1-20.1) 3 (2.8-3.1)
.1) 93/272 (34.2) 13 (7.2-17.1) 3 (2.9-3.1)
0/7 (0.0) NA NA
Memorial Sloan Kettering Cancer Center; NA ¼ not applicable; ORR ¼ objective response rate;
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Table 5 Safety Summary
MSKCC Intermediate Risk
n [ 363 (%)
IMDC Intermediate Risk
n [ 343 (%)
All-grade Grade ‡ 3 All-grade Grade ‡ 3
Any AE 276 (76.0) 158 (43.5) 263 (76.7) 154 (44.9)
Treatment-related 227 (62.5) 109 (30.0) 218 (63.6) 110 (32.1)
AESIsa 231 (63.6) 98 (27.0) 224 (65.3) 99 (28.9)
Treatment-related 210 (57.9) 86 (23.7) 203 (59.2) 89 (25.9)
SAEs 97 (26.7) 76 (20.9) 92 (26.8) 70 (20.4)
Treatment-related 38 (10.5) 31 (8.5) 34 (9.9) 28 (8.2)
Fatal SAEs 17 (4.7) 17 (4.7) 13 (3.8) 13 (3.8)
Treatment-related 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3)
AEs leading to treatment discontinuation 53 (14.6) 29 (8.0) 54 (15.7) 29 (8.5)
Treatment-related 39 (10.7) 21 (5.8) 43 (12.5) 24 (7.0)
AEs leading to dose adjustment/interruption 190 (52.3) 104 (28.7) 186 (54.2) 101 (29.4)
Abbreviations: AEs ¼ adverse events; AESI ¼ adverse events of special interest; IMDC ¼ International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC ¼ Memorial Sloan Kettering
Cancer Center; SAEs ¼ serious adverse events.
aAESIs were defined as any reports of new onset/worsened hypertension, cardiac dysfunction, thyroid dysfunction, evidence of liver toxicity, or any other AE resulting in a pazopanib dose modification
or discontinuation.
Table 6 Treatment-related Adverse Events
Any Grade
Occurring in
‡ 5% of Patients
in Either Group
MSKCC
Intermediate Risk
n [ 363 (%)
IMDC
Intermediate Risk
n [ 343 (%)
Hypertension 86 (23.7) 82 (23.9)
Diarrhea 45 (12.4) 47 (13.7)
ALT increased 45 (12.4) 42 (12.2)
AST increased 28 (7.7) 26 (7.6)
Hypothyroidism 21 (5.8) 24 (7.0)
Nausea 19 (5.2) 16 (4.7)
Blood TSH increased 15 (4.1) 18 (5.2)
Abbreviations: ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase;
TSH ¼ thyroid-stimulating hormone.
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Continuous variables were reported as medians and ranges; cat-
egorical variables were reported as number and percentage of the
total population. Evaluations were based on point estimates and
95% confidence intervals (CIs), and efficacy and safety analyses
were stratified by baseline patient characteristics (eg, ECOG PS,
histologic subtype). Formal hypothesis or statistical significance
testing was not planned.
Results
Patients
Of the 657 enrolled patients in the PRINCIPAL study who
received  1 dose of pazopanib (AT population), more than one-
half had intermediate-risk criteria per MSKCC (55.3%; n ¼ 363)
and IMDC (52.2%; n ¼ 343); MSKCC and IMDC risk data were
missing for 178 (27.1%) and 128 (19.5%) patients in the overall
population, respectively. Among the MSKCC and IMDC
intermediate-risk patients, 281 (77.4%) and 258 (75.2%)
completed the study, and 133 (36.6%) and 130 (37.9%) completed
the 30-month follow-up. One hundred and forty-eight (40.8%) in
the MSKCC intermediate-risk group and 128 (37.3%) in the
IMDC intermediate-risk group died. Discontinuation rates were
similar for both intermediate-risk groups (Table 1). Baseline patient
demographics and disease characteristics for intermediate-risk pa-
tients are shown in Table 2. Per MSKCC and IMDC criteria, 1 risk
factor was present for 147 (40.5%) and 171 (49.9%) patients,
respectively, and 2 risk factors were present for 141 (38.8%) and
133 (38.8%) patients, respectively. Most patients had an ECOG PS
of < 2.
Effectiveness
In both MSKCC and IMDC intermediate-risk groups, median
PFS and OS were numerically longer for patients who had 1 risk
factor compared with patients who had 2 risk factors. Median PFS- Clinical Genitourinary Cancer June 2019was 13.8 months (95% CI, 10.7-18.1 months) and 7.4 months
(95% CI, 6.2-10.3 months) for patients with 1 and 2 MSKCC risk
factors, respectively, and 13.1 months (95% CI, 10.7-18.1 months)
and 8.1 months (95% CI, 6.4-10.7 months) for patients with 1 and
2 IMDC risk factors, respectively (Table 3). Within these
intermediate-risk populations, the median OS was not reached and
was 15.2 months (95% CI, 12.3-26.5 months) for patients with 1
and 2 MSKCC risk factors, respectively, and 33.9 months (95% CI,
33.9 months to not estimable) and 19.4 months (95% CI, 14.3
months to not estimable) for patients with 1 and 2 IMDC risk
factors, respectively (Table 3). Shorter median PFS and OS were
observed in patients with ECOG PS  2 (vs. PS < 2) (Table 3).
Among patients with intermediate-risk, a lower ORR was
observed for those with ECOG PS  2 (vs. PS < 2). For patients
with ECOG PS < 2, the ORR was 33.7% and 34.2% by MSKCC
and IMDC intermediate-risk criteria, respectively, compared with
0% for patients with ECOG PS  2 by both MSKCC and IMDC
intermediate-risk criteria (Table 4).
Table 7 Adverse Events by Age (< 65 Versus ‡ 65 Years)
Any Grade Occurring
in ‡ 5% of Patients
in any Group
MSKCC Intermediate Risk
n [ 363 (%)
IMDC Intermediate Risk
n [ 343 (%)
< 65 Years
n [ 143
‡ 65 Years
n [ 220
< 65 Years
n [ 137
‡ 65 Years
n [ 206
Hypertension 38 (26.6) 52 (23.6) 41 (29.9) 47 (22.8)
ALT increased 21 (14.7) 25 (11.4) 19 (13.9) 24 (11.7)
Diarrhea 18 (12.6) 30 (13.6) 23 (16.8) 27 (13.1)
AST increased 15 (10.5) 15 (6.8) 14 (10.2) 13 (6.3)
Blood TSH increased 13 (9.1) 9 (4.1) 16 (11.7) 9 (4.4)
Nausea 11 (7.7) 11 (5.0) 10 (7.3) 9 (4.4)
Vomiting 9 (6.3) 6 (2.7) 7 (5.1) 4 (1.9)
Hypothyroidism 8 (5.6) 14 (6.4) 9 (6.6) 17 (8.3)
Asthenia 5 (3.5) 11 (5.0) 5 (3.6) 9 (4.4)
Fatigue 3 (2.1) 11 (5.0) 2 (1.5) 10 (4.9)
Hepatotoxicity 2 (1.4) 12 (5.5) 3 (2.2) 13 (6.3)
Abbreviations: ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; TSH ¼ thyroid-stimulating hormone.
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At least 1 adverse event (AE) was reported by most patients with
intermediate risk (MSKCC, 76.0%; IMDC, 76.7%), and most AEs
were related to treatment (MSKCC, 62.5%; IMDC, 63.6%)
(Table 5). The most commonly reported treatment-related AEs
( 5%) in the MSKCC and IMDC intermediate-risk groups were
hypertension, diarrhea, increased alanine aminotransferase,
increased aspartate aminotransferase, hypothyroidism, nausea, and
increased blood thyroid-stimulating hormone (Table 6). Treatment-
related serious AEs were reported by 38 (10.5%) MSKCC
intermediate-risk patients and 34 (9.9%) IMDC intermediate-risk
patients. Seventeen (4.7%) and 13 (3.8%) patients died in the
MSKCC and IMDC intermediate-risk groups, respectively; 1
(0.3%) death in each intermediate-risk group was considered related
to treatment. When pazopanib safety was assessed in intermediate-
risk patients aged  65 and < 65 years, the AE profile was generally
similar between the 2 age groups (Table 7).
Discussion
Prognostic risk models based on clinical and laboratory factors
not only predict survival for patients with advanced RCC but also
have become important tools to guide treatment choice in a
crowded therapeutic landscape. New treatment options have
recently emerged for intermediate- or poor-risk patients5,6; however,
it is unclear whether all intermediate-risk patients, who comprise a
heterogeneous patient group with 1 or 2 risk factors, should be
treated similarly. Such differential efficacy outcomes between risk
groups have been previously demonstrated in the CheckMate-214
trial, for example.5 In CheckMate-214, nivolumab plus ipilimu-
mab showed superior OS and ORR versus sunitinib in intermedi-
ate-/poor-risk patients (co-primary endpoints). Conversely, PFS and
ORR favored sunitinib in an exploratory analysis of favorable-risk
patients5; however, the difference in ORR between treatment
groups was no longer significant in an updated analysis after a
minimum of 30 months’ follow-up (updated PFS not reported).14
The current secondary analysis of the PRINCIPAL study in-
vestigates intermediate-risk subgroups for differences in outcomes. Anearlier primary analysis of the PRINCIPAL study demonstrated that
the PFS of the overall MSKCC and IMDC intermediate-risk patients
was 11.2months (95%CI, 9.5-13.7months) and 11.6months (95%
CI, 9.8-14.1 months), respectively; OS was 33.9 months (95% CI,
26.9months to not reached) and 32.9months (95%CI, 28.6months
to not reached), respectively. In this large prospective real-world
study, intermediate-risk patients with 1 risk factor by both MSKCC
and IMDC criteria had longer median PFS and OS with pazopanib
compared with patients with 2 risk factors. Clinical outcomes were
also worse for patients with poor ECOGPS ( 2) versus patients with
ECOG PS < 2. These results highlight the heterogeneity of the
intermediate-risk group. Further, our findings are consistent with
previous retrospective analyses of intermediate-risk advanced RCC
patients undergoing targeted therapy, which found prolonged PFS
andOS in patients with 1 risk factor compared with 2 risk factors10-12
and in patients with poorer ECOGPS (0 vs. 1-2).11 Findings from the
secondary analysis of the PRINCIPAL study suggest that patients
with advanced RCC of intermediate prognostic risk can be further
stratified, by 1 risk factor (intermediate-low) versus 2 risk factors
(intermediate-high) or ECOG PS to more accurately predict treat-
ment outcomes. These findings may further aid treatment choice for
patients classified as having intermediate risk, particularly if applied to
clinical trials of immuno-oncologic regimens versus tyrosine kinase
inhibitor therapy.
Pazopanib treatment among intermediate-risk patients was
generally well-tolerated. A relatively low frequency of hypertension,
diarrhea, alanine aminotransferase elevations, and aspartate amino-
transferase elevations were observed compared with past clinical trial
data, possibly owing to the observational nature of PRINCIPAL.
Further, we noted similar safety profiles for patients in the older
( 65 years) and younger (< 65 years) age groups, which supports a
role for pazopanib in the treatment of patients of all ages with
advanced RCC.
Conclusions
Patients with intermediate-risk advanced RCC treated with
pazopanib in the prospective observational PRINCIPAL studyClinical Genitourinary Cancer June 2019 - e531
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ECOG PS (< 2 vs.  2) to more accurately predict effectiveness
outcomes. It should be noted that only a small group of patients
with ECOG PS  2 were included in our analyses. The results have
implications for treatment choice in intermediate-risk patients, who
are currently prescribed similar treatments regardless of the number
or type of risk factors or PS.
Clinical Practice Points
 Prognostic risk models such as those developed by MSKCC and
the IMDC are important tools for guiding treatment choices for
patients with advanced RCC.
 With the emergence of newer treatments for patients with in-
termediate- or poor-risk RCC, it has become unclear whether all
intermediate-risk patients should be treated similarly, given that
this population comprises a heterogenous group having either 1
or 2 risk factors.
 A secondary analysis of the prospective PRINCIPAL study was
conducted to evaluate real-world effectiveness and safety of
pazopanib within MSKCC and IMDC intermediate-risk group
patients according to subgroups by number of risk factors (1 vs.
2), age (< 65 vs.  65 years) and ECOG PS (< 2 vs.  2).
 Patients with MSKCC or IMDC intermediate risk having 1 risk
factor had longer median PFS and OS with pazopanib than
patients with 2 risk factors. Similar clinical outcomes were seen
in patients with ECOG PS < 2 in comparison to those with
ECOG PS  2.
 Results of this secondary analysis highlight the heterogeneity of
the intermediate-risk group and suggest that these patients can be
further stratified, either by number of risk factors (1 ¼ inter-
mediate-low vs. 2 ¼ intermediate-high) or ECOG PS, to more
accurately predict treatment outcomes.
 These findings provide important considerations concerning
treatment choices for patients classified as having intermediate-risk
RCC, and further have potential implications for future clinical
trials of immuno-oncologic regimens versus TKI therapies.Acknowledgments
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